Clinical Trial to Investigate the Pharmacokinetics of Second-Line Anti-Tuberculosis Agents
Primary Purpose
Healthy
Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Levofloxacin and Streptomycin added
Moxifloxacin and Kanamycin added
Sponsored by
About this trial
This is an interventional treatment trial for Healthy focused on measuring Antituberculosis agents, Pharmacokinetics
Eligibility Criteria
Inclusion Criteria:
- healthy male subject aged 20 to 50 at screening
- a body weight in the range of 55 kg (inclusive) to 90 kg (inclusive) with ideal body weight range of 19.0 to 26.0 subjects who decide to participate voluntarily and write a informed consent form
Exclusion Criteria:
- subjects who have clinically significant disease of cardiovascular, respiratory, renal, endocrinological, hematological, gastrointestinal, neurological(central nervous system), psychiatric disorders or malignant tumor
- subject judged not eligible for study participation by investigator.
Sites / Locations
- Seoul National University Bundang Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Levofloxacin and Streptomycin added
Moxifloxacin and Kanamycin added
Arm Description
Levofloxacin and Streptomycin added : Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Levofloxacin 750mg (500mg x 1.5 tab) qd, Streptomycin 1g IM qd
Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Moxifloxacin 400mg (400mg x 1 tab) qd, Kanamycin 1g IM qd
Outcomes
Primary Outcome Measures
AUC (area under the plasma concentration-time curve)
AUC (Area under the plasma concentration versus time curve), Cmax(maximum plasma concentration)
Secondary Outcome Measures
Full Information
NCT ID
NCT02128308
First Posted
April 28, 2014
Last Updated
April 29, 2014
Sponsor
Seoul National University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02128308
Brief Title
Clinical Trial to Investigate the Pharmacokinetics of Second-Line Anti-Tuberculosis Agents
Official Title
A Open-label, Single Sequence Clinical Trial to Investigate the Pharmacokinetic Characteristics of Second-Line Anti-Tuberculosis Agents After Multiple Oral/Intramuscular Administration in Healthy Male Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
April 2014
Overall Recruitment Status
Completed
Study Start Date
November 2013 (undefined)
Primary Completion Date
December 2013 (Actual)
Study Completion Date
January 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study aims to investigate the pharmacokinetic characteristics of second-line anti-tuberculosis agents after oral/intramuscular administration in healthy male volunteers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy
Keywords
Antituberculosis agents, Pharmacokinetics
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
16 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Levofloxacin and Streptomycin added
Arm Type
Experimental
Arm Description
Levofloxacin and Streptomycin added : Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Levofloxacin 750mg (500mg x 1.5 tab) qd, Streptomycin 1g IM qd
Arm Title
Moxifloxacin and Kanamycin added
Arm Type
Experimental
Arm Description
Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Moxifloxacin 400mg (400mg x 1 tab) qd, Kanamycin 1g IM qd
Intervention Type
Drug
Intervention Name(s)
Levofloxacin and Streptomycin added
Other Intervention Name(s)
Cycloserine, P-aminosalicylic acid, Prothionamide, Pyrazinamide, levofloxacin, steptomycin
Intervention Type
Drug
Intervention Name(s)
Moxifloxacin and Kanamycin added
Other Intervention Name(s)
Cycloserine, P-aminosalicylic acid, Prothionamide, Pyrazinamide, moxifloxacin, kanamycin
Primary Outcome Measure Information:
Title
AUC (area under the plasma concentration-time curve)
Description
AUC (Area under the plasma concentration versus time curve), Cmax(maximum plasma concentration)
Time Frame
Predose and 2d 0h, 3d 0h, 4d 0h, and 5d 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24h postdose
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
healthy male subject aged 20 to 50 at screening
a body weight in the range of 55 kg (inclusive) to 90 kg (inclusive) with ideal body weight range of 19.0 to 26.0 subjects who decide to participate voluntarily and write a informed consent form
Exclusion Criteria:
subjects who have clinically significant disease of cardiovascular, respiratory, renal, endocrinological, hematological, gastrointestinal, neurological(central nervous system), psychiatric disorders or malignant tumor
subject judged not eligible for study participation by investigator.
Facility Information:
Facility Name
Seoul National University Bundang Hospital
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
25987620
Citation
Park SI, Oh J, Jang K, Yoon J, Moon SJ, Park JS, Lee JH, Song J, Jang IJ, Yu KS, Chung JY. Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers. Antimicrob Agents Chemother. 2015 Aug;59(8):4429-35. doi: 10.1128/AAC.00354-15. Epub 2015 May 18.
Results Reference
derived
Learn more about this trial
Clinical Trial to Investigate the Pharmacokinetics of Second-Line Anti-Tuberculosis Agents
We'll reach out to this number within 24 hrs